



NAME OF APPLICANT	Yingyao Chen
MEMBER IN GOOD STANDING	Yes
RECOMMENDED BY SOCIETY MEMBERS IN GOOD STANDING	Wija Oortwijn Clifford Goodman
POSITION APPLYING FOR	Director
ORGANIZATION NAME	Fudan University
ORGANIZATION TYPE	Academia
POSITION WITH COMPANY	Deputy Dean, School of Public Health Director, NHC Key Lab of Health Technology Assessment Director, WHO Collaborating Center for HTA
COUNTRY OF RESIDENCE	China
CONFLICT OF INTEREST	
ARE YOU CURRENTLY SERVING ON ANY BOARDS?	No.
IF YES, WHICH BOARD?	-
CAN THIS SERVICE ON ANOTHER BOARD GIVE RISE TO A CONFLICT OF INTEREST WITH HTAi BOARD SERVICE?	No
IF YES, PLEASE DECLARE YOUR CONFLICT OF INTEREST.	-
DO YOU HAVE ANY CONTRACTUAL AGREEMENTS WITH HTAi FOR SERVICES?	No
IF YES, PLEASE SPECIFY.	-
DO YOU HAVE ANY AFFILIATIONS, MEMBERSHIPS, CONTRACTS OR SPECIAL INTERESTS CONFLICTING WITH THE ROLE AND DUTIES AS AN HTAi DIRECTOR?	No
IF YES, PLEASE DECLARE YOUR CONFLICT OF INTEREST.	-
APPLICANT EXPERIENCE	
LEADERSHIP EXPERIENCE	Academia
PREVIOUS BOARD SERVICE. YES/NO	Yes
IF YES:	
HOW MANY YEARS?	<ol style="list-style-type: none"> HTAi Board of Directors - 3 years INAHTA Board – 1 year (while serving on HTAi Board) HTAi Board Observer – 1 year
WHICH BOARD POSITION?	<ol style="list-style-type: none"> Director Observer

EXPERIENCE IN LEADERSHIP AND GOVERNANCE OF NOT-FOR-PROFIT AND FOR-PROFIT ORGANIZATIONS. YES/NO	Yes.
IF YES:	
HOW MANY YEARS?	13 Years.
TYPE OF EXPERIENCE	Deputy Dean of School for Public Health, Fudan University 2013- ; Director of NHC Key Lab of Health Technology Assessment 2013- ; Director of WHO Collaborating Center for HTA and Management 2013-
LEVEL OF MANAGEMENT EXPERIENCE	Top Level of Management
EXPERIENCE CHAIRING BOARD OR COMMITTEE YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	<ol style="list-style-type: none"> 1. Co-Chair HTAi International Scientific Program Committee for 2026 Annual Meeting 2. Interest Group Advisory Committee
NUMBER OF YEARS	<ol style="list-style-type: none"> 1. 1 year 2. 3 years
PUBLIC SPEAKING EXPERIENCE YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	<p>Examples of recent talks I have given:</p> <ol style="list-style-type: none"> 1. Health Technology Assessment Development in China and Its Experience, the Hong Kong Pharmacy Conference (HKPC) January 2026 2. Health Technology Assessment Empowering Health System Innovation Development, Health Technology Assessment Conference, December 2025, Beijing China 3. Real World Study Supporting Value Assessment for Medical Devices, Hainan Real World Study Conference, December 2025, Boao China 4. Advance of HTA (Process and Framework) for Access Decision Making on Oncology Innovative Drugs, Oncology Innovative Treatments Value Assessment Symposium, November 2025, Thailand
NUMBER OF YEARS	25 years
DO YOU UNDERSTAND THE DIFFERENCE BETWEEN GOVERNANCE AND MANAGEMENT	Yes. My understanding of the difference between governance and management is as follows: Governance is the overall process of decision-making and policy development that sets the direction for the organization. It involves establishing the values, vision, and goals of the organization, as well as developing policies and procedures to achieve them. Management, on the other hand, is the process of implementing the policies and

	<p>procedures established by the governing body. It involves organizing resources, supervising staff, and making day-to-day decisions to ensure that the organization operates efficiently and effectively. In summary, governance sets the overall direction and policy framework for the organization, while management is responsible for implementing those policies and ensuring the organization operates effectively.</p> <p>I have 13 years' experience in management and governance as the Director and Deputy Dean of the School of Public Health at Fudan University.</p>
STRATEGIC PLANNING EXPERIENCE? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	I have been the Director of the NHC Key Lab of HTA for more than 10 years, and I have experience drafting 1-year and 5-year strategic plannings for this. I also have experience implementing the plan and receiving performance evaluation. NHC Key Lab of HTA, as a leading national HTA agency, reflects our achievement in general, also we realized that we have some weaknesses.
NUMBER OF YEARS	10+ years
EXPERIENCE IN DEVELOPING GROWTH STRATEGIES AND PLANS? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	Here's an example of my experience as the Director of the Key Lab of Health Technology Assessment, National Health Commission (Fudan University), in developing growth strategies and plans: I have conducted a comprehensive SWOT for our lab and developed a vision and mission statement. I have engaged with a wide range of stakeholders, including faculty, staff, students, government agencies, and industry partners, to gather input and feedback on the growth strategies and plans. This has enabled us to build a shared vision and a sense of ownership among stakeholders. Based on the SWOT analysis, vision and mission statement, KPIs, and stakeholder input, I have developed a strategic plan that outlines specific growth strategies and action plans to achieve our goals. This plan includes timelines, resource requirements, and risk mitigation strategies. I have monitored progress against key performance indicators, evaluated results, and made adjustments as necessary to ensure successful implementation of the strategic plan.
NUMBER OF YEARS	13 years

MEMBERSHIP RECRUITMENT AND ENGAGEMENT EXPERIENCE? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	Though I don't have direct membership recruitment and engagement experiences at HTAi, I have some similar experiences to grow participants of the China Health Technology Assessment Forum by our key lab at Fudan from around 100 to around 500 in five years. I think that the most important thing is to create value for members/participants, and to listen to the potential target people's voices and their needs. Other experience that could be relevant to this is that I have had more than 150 master's and PhD students (120 graduated). I have plenty of experiences to recruit new students and to foster them.
NUMBER OF YEARS	13 years
PARTNERSHIP DEVELOPMENT EXPERIENCE? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	In 2019 and 2020, I gained significant partnership development and fundraising experience while preparing for the HTAi Annual Meeting in Beijing. Working closely with the HTAi Secretariat, CNHDRC, and various stakeholders, I developed a deep understanding of HTAi's strategic approaches and expectations. I successfully engaged with industry partners to secure fundraising commitments—efforts that were highly promising before the meeting was unfortunately impacted by the pandemic. Beyond this specific event, I have a proven track record of building extensive global networks. I initiated and currently coordinate the South-South Collaboration Public Health Education Network (SSPHEN), which has expanded to nearly 50 member organizations across more than 18 countries.
NUMBER OF YEARS	13 years
PROGRAMS' EVALUATION EXPERIENCE? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	I have a course for graduate students, health service program evaluation. I have many grants or contracts for program evaluation, such as national medical equipment allocation policy, national prenatal diagnosis service system, hospital continuous quality improvement program in a city, etc.
NUMBER OF YEARS	23 years
FINANCIAL OVERSIGHT	

FINANCIAL LITERACY? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	One of my research expertise is economic evaluation, including cost analysis.
NUMBER OF YEARS	25 years
EXPERIENCE WITH FINANCIAL STATEMENTS AND VARIANCE ANALYSIS? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	My experience is from my research projects, mainly hospital financial statement and analysis in China. I also have 2-years experience as a member of Finance & Audit Committee at HTAi.
NUMBER OF YEARS	25 years
EXPERIENCE WITH FINANCIAL RISK IDENTIFICATION AND ASSESSMENT? YES/NO	Yes
IF YES:	
TYPE OF EXPERIENCE	I did some break-even analysis, budget impact analysis, risk assessment and others in my research projects. However, I have not experience to do financial assessment for an international entity such as HTAi.
NUMBER OF YEARS	25 years
COMMITTEE WORK	
WHICH BOARD ADVISORY COMMITTEES ARE YOU INTEREST TO SERVE ON?	Business Development Committee, Interest Group Advisory Committee.
EXPLAIN WHY YOU SELECTED THE ABOVE COMMITTEES	I am interested to serve on the Interest Groups Advisory Committee and Business Development Committee since they are full of challenges for me. I strongly feel that all IGs are active cells of the society to make HTAi outstanding in the global community through standardized governance with diverse autonomous patterns, better operation and sustainable development by IG members, executives and technical officers and HTAi secretariat. I believe that IGs strategy is one of the most important strategies for HTAi.
WHICH BOARD ADVISORY COMMITTEE(S), IF AVAILABLE, WOULD YOU BE INTERESTED TO CHAIR IN THE NEAR FUTURE?	Business Development Committee.
EXPLAIN WHY YOU SELECTED THE ABOVE COMMITTEE(S)	I think that the Business Development Committee is closely linked with the strategic planning and can make HTAi more visible, viable, powerful and a leading status globally.
WOULD YOU BE INTERESTED IN BECOMING THE HTAi BOARD LIAISON	Yes

FOR THE IJTAHC IN THE NEAR FUTURE? YES/NO	
IF YES, PLEASE EXPLAIN YOUR EXPERTISE WITH ACADEMIC PUBLISHING/WRITING AND/OR SERVING ON EDITORIAL BOARDS OF INTERNATIONAL, PEER- REVIEWED JOURNALS.	I am an editorial board member of IJTAHC Journal and the Pharmacoeconomics Journal.

Resume

Professor Yingyao Chen is Professor of Health Technology Assessment at Fudan University School of Public Health, (FUSPH), Director of the National Health Commission Key Laboratory of Health Technology Assessment at Fudan University, and Director of World Health Organization (WHO) Collaborating Centre for Health Technology Assessment, Shanghai, China. In addition, he is the Associate Dean of the FUSPH, responsible for international collaborations.

He received his Bachelor of Medicine and Master of Public Health at Shanghai Medical University in 1991 and 1997, respectively, and his PhD in Management at Fudan University in 2006. He took part in a visiting scholar programme at the University of California, Los Angeles from 1999 to 2001.

His academic interests focus on health technology assessment, hospital management and health systems strengthening. He was a principal investigator of projects funded by the WHO, World Bank, New Development Bank, China Medical Board, National Health Commission (former Ministry of Health), Ministry of Science and Technology, National Health Security Administration, National Natural Science Foundation of China (NSFC), and provincial health and health security authorities. He has published 200 papers (30 in English) as the first author and/or corresponding author. He is the Editor-in-chief of *Health Technology Assessment*, *Health Services Evaluation*, *Hospital Human Resource Management*, *Evidence Based Health Care Decision and Management*, and *Disease Burdens of Main Birth Defects and Economic Evaluation of Their Preventive Strategies in China*. He was also one of core members to draft the Guideline for Health Technology Assessment in China.

He is the Vice-Chairman of the Health Technology Economic Evaluation Committee affiliated to China Health Economics Association, Chairman of the Health Technology Assessment Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Committee of the China Association for Medical Devices Industry (elected), a standing committee member of Birth Defects Prevention and Management affiliated to Chinese Preventive Medicine Association. He served as one of WHO Expert Members for Guideline on Country Pharmaceutical Pricing Policies, WHO TAG on Health Benefit Packages, the Co-Chair of the Cochrane China Network Executive Committee (2022), a member of board of directors of Health Technology Assessment international (HTAi) (2016-2019) and an observer at HTAi (2020).

His HTA research projects covered pharmaceuticals (*such as immunotherapy, targeted drugs, anti-diabetes drugs, anti-hypertension drugs*), medical devices (*such as devices for paroxysmal atrial fibrillation, mitral regurgitation, robotic surgical system*), equipment (*such as CT, MRI*), screening (*such as for Down's syndrome, thalassemia, neonatal genetic metabolic diseases, congenital heart diseases, HPV*), clinical procedures (*such as ozonated autohemotherapy, assisted reproductive technology*), AI-HTA development and validation, patient preference (*people with lung cancer, diabetes, and mental health*), knowledge translation (*from HTA to macro-, meso-, and micro- policy making*), HTA system development (international experiences and China practice).

He and his Fudan team organize China HTA Forum in the fall every year, which is a national-wide HTA platform for policymakers, academia, healthcare providers, NGOs, industry, and young students. He produced the first Chinese Massive Open Online Course (MOOC) in HTA (Chinese with English subtitles), which received the National Excellent MOOC Award, and promoted HTA knowledge among the Chinese audience.

An overview of my experience and qualifications relating to the Board of Directors Criteria and Core Competencies

By Yingyao Chen, PhD

I would like to demonstrate my experience and qualifications by introducing my activities at HTAi. I have been an HTAi member around 28 years, and I appreciate HTAi empowered my career development. I served one term on the Board of Directors from 2016-2019 and an observer in 2020. I participate many HTAi activities, such as the Interest Group Steering Committee (IGSC), the Finance & Audit Committee, the Scientific Development and Capacity Building Committee (SDCB), the Annual Meeting Committee, the Asia Policy Forum Organization Committee, and witness the society rapid and sustainable development as a leading role in the field of HTA globally. I am proud to be a member of HTAi, and I want to contribute further to our community.

In 2025, I was enthusiastic to work with peers to learn, to communicate, and share experiences and knowledge of HTA. I joined three panels at HTAi annual meeting 2025, discussing reassessment of innovative drugs on reimbursement lists in Australia, China, South Korea, and USA, presenting applications of HTA in benefit plan design in Argentina, China India and some South American countries, and exploring the challenge and benefits of HTA, academia and government collaborations in Australia, China and Malaysia. **These experiences truly embody the spirit of Collaboration.**

I also enjoyed attending the HTAsiaLink meeting in Singapore 2025. I felt diverse health systems in Asia, different HTA patterns or progress. I acted as a reviewer for some oral presentations on sites, but I felt fortunate to be exposed to many new HTA cases with high quality. Also, I encourage my students to submit the abstracts to the international meetings and bring young generations to the professional arenas, and we gained valuable insights from many perspectives. I feel it is **Capacity Building**, and **Mutual Learning**.

I serve as the Co-chair of the International Scientific Program Committee (ISPC) of HTAi annual meeting 2026. I am very excited to work with around 40 members and the secretariate team through the virtual meetings and emails. We openly discussed the themes for the meeting and plenaries, reached a consensus on “HTA As A System Shaper”, and explored how to response to the new challenges (such as AI, digital, and others), and to work together to complete many missions successfully so far. I appreciate Eva, Abdullah, executive members, all members, and the secretariate. I feel it is **Teamwork** for the same goal, and **Good Governance and Effective Mechanism**.

I think that those activities to reflect my passion for HTAi, and my competence and capacity on governance, knowledge & judgement, participation, collaboration, teamwork, etc.

I would like to advocate the following recommendations for HTAi:

First, to be more involved in global health governance.

HTAi is one of the most unique and leading international organizations in this field, and it should be more ambitious to play roles in global health governance. With significant economic pressure globally, HTA provides valuable evidence to support quality, cost-effective and appropriate use (including disinvestment) of health technologies at macro and micro levels. I think that HTAi should be more active to be involved in global health governance, through WHO and its regional authorities, other health international agencies or NGOs to serve for high-, middle- and low- income countries with different strategies, priorities and paths. HTAi and its IG groups to provide technical input to support the development of new methodology, guidelines, consensus, technical papers on HTA of new health technologies, such as AI and digital health. HTAi should make itself outstanding independently.

Second, to be more committed to members' capacity building.

HTAi relies on members' engagements & supports, I recommend that HTAi should develop more attractive HTA programs or activities to serve the members regularly by different approaches or channels, and produce additional value to meet diverse members' needs. For example, HTAi and its IGs produce more webinars/mentoring programs, with functions of knowledge sharing on hot topics, and creating a global HTA hub for capacity building, education, mentoring or mutual-learning activities, to foster the new generation or the new-comers of HTA community, etc. It might require not only structural adjustments within HTAi system and mechanism within the society, but also initiatives taken in implementation by supports from all stakeholders, such as board members, committees, IGs, all members and the secretariats.

Third, to contribute more to LMIC health system strengthening

HTAi accumulates plenty of HTA knowledge, experiences, expertise and intangible resources, while LMICs are looking for how to adapt HTA into their settings. HTAi should bear this responsibility and engage in emerging HTA markets by seeking new ways to connect our members with the broader HTA new areas. HTAi's annual meetings and policy fora are wonderful assets, the regional meeting or country meetings are successful pilot models, and we need more such endeavors in Africa, Asia, and South America. LMICs urgently need HTA to inform policy making in health sector, especially strategic purchasing for health services. I recommend to facilitate to bridge HTAi with HTA stakeholders in LMICs, including policymakers, researchers, providers, patients, industry, and other stakeholders.

In addition, I am also enthusiastic about advocating for Shanghai, China, as a host city for a future HTAi Annual Meeting. It is a dream for HTA person in China, we can learn more from HTAi members, and we can serve for you.

Please vote for me, and give me the opportunity to serve for every HTAi members!